This meta- analysis concludes that l-arginine supplementation can significantly reduce blood TAG levels ; however , there is insufficient evidence to support its hypocholesterolaemic effects .
A number of clinical trials have examined the effect of l-arginine on lipid profile in recent years ; however , the results remain equivocal .
Therefore , the present study aims to summarise and quantitatively examine the available evidence on the effectiveness l-arginine supplementation on lipid parameters using a systematic review and meta-analytic approach .
Oral L-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass.
It is known that L-arginine treatment can ameliorate endothelial dysfunction and insulin sensitivity in type 2 diabetes mellitus patients , but little is known on L-arginine effects on these variables in nondiabetic patients with stable cardiovascular disease ( coronary artery disease ) . We evaluated the effects of long-term oral L-arginine treatment on endothelial dysfunction , inflammation , adipokine levels , glucose tolerance , and insulin sensitivity in these patients . Sixty-four patients with cardiovascular disease previously su bmi tted to an aortocoronary bypass and not known for type 2 diabetes mellitus had an oral glucose load to define their glucose tolerance . Thirty-two patients with nondiabetic response were eligible to receive , in a double-blind r and omized parallel order , L-arginine ( 6.4 g/d ) or placebo for 6 months . An evaluation of insulin sensitivity index during the oral glucose load , markers of systemic nitric oxide bioavailability and inflammation , and blood flow was performed before and at the end of the treatment in both groups . Compared with placebo , L-arginine decreased asymmetric dimethylarginine levels ( P < .01 ) , indices of endothelial dysfunction , and increased cyclic guanosine monophosphate ( P < .01 ) , L-arginine to asymmetric dimethylarginine ratio ( P < .0001 ) , and reactive hyperemia ( P < .05 ) . Finally , L-arginine increased insulin sensitivity index ( P < .05 ) and adiponectin ( P < .01 ) and decreased interleukin-6 and monocyte chemoattractant protein-1 levels . In conclusion , insulin resistance , endothelial dysfunction , and inflammation are important cardiovascular risk factors in coronary artery disease patients ; and L-arginine seems to have anti-inflammatory and metabolic advantages in these patients
This meta- analysis concludes that l-arginine supplementation can significantly reduce blood TAG levels ; however , there is insufficient evidence to support its hypocholesterolaemic effects .
A number of clinical trials have examined the effect of l-arginine on lipid profile in recent years ; however , the results remain equivocal .
Therefore , the present study aims to summarise and quantitatively examine the available evidence on the effectiveness l-arginine supplementation on lipid parameters using a systematic review and meta-analytic approach .